Status:
COMPLETED
The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
Lead Sponsor:
Charles University, Czech Republic
Conditions:
Sepsis Syndrome
Systemic Inflammatory Response Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to measure serum levels of myristic acid in septic patients and to compare them with myristic acid serum levels in patients with Systemic Inflammatory Response Syndrome of non ...
Detailed Description
Currently, there is an array of biomarkers potentially useful in diagnosis and prognosis in septic patients, either alone or in combination. Only a fraction of them is used in clinical practice. The r...
Eligibility Criteria
Inclusion
- Sepsis or septic shock.
- Systemic inflammatory response syndrome.
- Subjects without systemic inflammation.
Exclusion
- There is no exclusion criteria in the study
Key Trial Info
Start Date :
October 24 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
282 Patients enrolled
Trial Details
Trial ID
NCT03314831
Start Date
October 24 2017
End Date
December 31 2022
Last Update
February 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Anesthesiology and Intensive Care, First Faculty of Medicine, Charles University and Thomayer Hospital
Prague, Czechia, 14059